PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer.
Chen A, Kim BJ, Mitra A, Vollert CT, Lei JT, Fandino D, Anurag M, Holt MV, Gou X, Pilcher JB, Goetz MP, Northfelt DW, Hilsenbeck SG, Marshall CG, Hyer ML, Papp R, Yin SY, De Angelis C, Schiff R, Fuqua SAW, Ma CX, Foulds CE, Ellis MJ.
Chen A, et al. Among authors: ma cx.
Mol Cancer Ther. 2024 Oct 1;23(10):1494-1510. doi: 10.1158/1535-7163.MCT-23-0564.
Mol Cancer Ther. 2024.
PMID: 38781103
Free PMC article.